Literature DB >> 24630786

Risk of sudden death and outcome in patients with hypertrophic cardiomyopathy with benign presentation and without risk factors.

Paolo Spirito1, Camillo Autore2, Francesco Formisano3, Gabriele Egidy Assenza2, Elena Biagini4, Tammy S Haas5, Sergio Bongioanni6, Christopher Semsarian7, Emmanuela Devoto3, Beatrice Musumeci2, Francesco Lai4, Laura Yeates7, Maria Rosa Conte6, Claudio Rapezzi4, Luca Boni8, Barry J Maron5.   

Abstract

Patients with hypertrophic cardiomyopathy (HC) are reported to have a mortality rate of about 1.0% per year, and those patients without sudden death risk factors and with no or mild symptoms are generally considered to have a benign clinical presentation. However, the risk of sudden death and the outcome in this latter subgroup have not been investigated systematically and remain unresolved. We assessed the risk of sudden death and outcome in 653 consecutive patients with HC without risk factors and with no or mild symptoms. Over a median follow-up of 5.3 years, 35 patients (5.4%) died of HC-related causes. Mean age at death was 46 ± 20 years in patients who died suddenly and 66 ± 15 and 72 ± 9 years, respectively, in patients who died of heart failure or stroke. Event rate was 0.6% per year for sudden death, 0.2% per year for heart failure death, and 0.1% per year for stroke-related death. Sudden death risk was independently and inversely related to age, and risk of heart failure or stroke death was directly related to age (p = 0.020). At 10 years after the initial evaluation, sudden death risk was 5.9%, with sudden death rate being the lowest (0.3% per year) in patients with normal left atrial dimension (≤40 mm). In conclusion, in patients with HC without conventional risk factors and with no or mild symptoms, the risk of sudden death was not negligible, with an event rate of 0.6% per year. Heart failure and stroke-related death were less common and largely confined to older patients. These results underscore the need for a more accurate assessment of the sudden death risk in patients with HC.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24630786     DOI: 10.1016/j.amjcard.2014.01.435

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  30 in total

1.  Recommendations of the current guidelines for implantable cardioverter-defibrillator implantation in patients with hypertrophic cardiomyopathy: Debate still exists.

Authors:  Arya Aminorroaya; Ali Vasheghani-Farahani; Farzad Masoudkabir; Pegah Roayaei
Journal:  J Interv Card Electrophysiol       Date:  2020-07-25       Impact factor: 1.900

Review 2.  Linking myofilaments to sudden cardiac death: recent advances.

Authors:  Sabine Huke
Journal:  J Physiol       Date:  2017-03-16       Impact factor: 5.182

3.  Prognostic impact of mitral L-wave in patients with hypertrophic cardiomyopathy without risk factors for sudden cardiac death.

Authors:  Yuki Sugiura; Ryota Morimoto; Soichiro Aoki; Shogo Yamaguchi; Tomoaki Haga; Tasuku Kuwayama; Tsuyoshi Yokoi; Hiroaki Hiraiwa; Toru Kondo; Naoki Watanabe; Naoaki Kano; Kenji Fukaya; Akinori Sawamura; Takahiro Okumura; Toyoaki Murohara
Journal:  Heart Vessels       Date:  2019-05-31       Impact factor: 2.037

4.  Enhanced American College of Cardiology/American Heart Association Strategy for Prevention of Sudden Cardiac Death in High-Risk Patients With Hypertrophic Cardiomyopathy.

Authors:  Martin S Maron; Ethan J Rowin; Benjamin S Wessler; Paula J Mooney; Amber Fatima; Parth Patel; Benjamin C Koethe; Mikhail Romashko; Mark S Link; Barry J Maron
Journal:  JAMA Cardiol       Date:  2019-07-01       Impact factor: 14.676

Review 5.  Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy.

Authors:  Ali J Marian; Eugene Braunwald
Journal:  Circ Res       Date:  2017-09-15       Impact factor: 17.367

6.  Atrial Fibrillation and Anticoagulation in Hypertrophic Cardiomyopathy.

Authors:  C Fielder Camm; A John Camm
Journal:  Arrhythm Electrophysiol Rev       Date:  2017-06

Review 7.  Atrial Fibrillation in Hypertrophic Cardiomyopathy: Diagnosis and Considerations for Management.

Authors:  Monica Patten; Simon Pecha; Ali Aydin
Journal:  J Atr Fibrillation       Date:  2018-02-28

8.  Analysis of SCN5A Gene Variants in East Slovak Patients with Cardiomyopathy.

Authors:  Mariana Priganc; Michaela Zigová; Iveta Boroňová; Jarmila Bernasovská; Dana Dojčáková; Viktória Szabadosová; Marta Mydlárová Blaščáková; Iveta Tóthová; Ján Kmec; Ivan Bernasovský
Journal:  J Clin Lab Anal       Date:  2016-08-24       Impact factor: 2.352

Review 9.  Hypertrophic cardiomyopathy: genetics and clinical perspectives.

Authors:  Cordula Maria Wolf
Journal:  Cardiovasc Diagn Ther       Date:  2019-10

10.  Comparison of Outcomes in Patients With Nonobstructive, Labile-Obstructive, and Chronically Obstructive Hypertrophic Cardiomyopathy.

Authors:  Iraklis Pozios; Celia Corona-Villalobos; Lars L Sorensen; Paco E Bravo; Marco Canepa; Chiara Pisanello; Aurelio Pinheiro; Veronica L Dimaano; Hongchang Luo; Zeina Dardari; Xun Zhou; Ihab Kamel; Stefan L Zimmerman; David A Bluemke; M Roselle Abraham; Theodore P Abraham
Journal:  Am J Cardiol       Date:  2015-06-26       Impact factor: 2.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.